NCT05514171

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline

PROSPECTIVE REGISTRY OF PATIENTS WITH BORDERLINE AND RESECTABLE PANCREATIC ADENOCARCINOMA IN CATALONIA (PaNLoCat)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 300 (actual)
• Sponsor: Hospital del Mar · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Unlike other types of gastrointestinal tumors, there is controversial evidence of the efficacy of neoadjuvant therapy in patients with borderline and resectable adenocarcinoma (ADK) of the pancreas, the objective of this study is to perform a "snapshot" of the usual practice in our setting in terms of neoadjuvant therapy in ADK, both in terms of the different regimens used as well as the results in terms of morbidity, mortality and survival. Likewise, in a second phase, a prospective registry of patients included in the neoadjuvant regimen for both resectable and borderline ADK diagnosed in Catalonia will be launched, which will provide us with valuable information to try to answer open questions in the context of borderline and resectable ADK treatment.

Conditions

• Chemotherapy Effect
• Pancreas Cancer

Interventions

Type	Name	Description
PROCEDURE	Neoadyuvant therapy	Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery

Timeline

• Start date: 2023-01-01
• Primary completion: 2023-06-30
• Completion: 2023-12-31
• First posted: 2022-08-24
• Last updated: 2024-06-07

Locations

1 site across 1 country: Spain